A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies
Volunteers
Health Professionals
What is the purpose of this trial?
This open-label Phase 2 study will evaluate the safety and efficacy of modified T cells (JCAR017) administered to adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL). The study will also help determine how long the modified T cells stay in the patient's body. Furthermore, changes in the patient's quality of life will be described. Phase 2 (autologous T cells expressing anti-CD19 chimeric antigen receptor) (DLBCL NOS [de novo or tFL], follicular lymphoma Grade 3B [FL3B], high grade B-cell Lymphoma [HGBL] and primary central nervous system lymphoma [PCNSL]).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Alfredo Axtmayer
- Amer Zeidan, MBBS
- Amy Pugliese
- Carolyn Demsky, APRN
- Ethan Kohn
- Francine Foss, MD
- Kaitlin Brown
- Kerri Ann Rall
- Lisa Rivera
- Lohith Gowda, MD, MRCP
- Manoj M Pillai, MBBS
- Maureen McGlennon
- Meifeng Shen
- Michael Hurwitz, MD, PhD
- Noffar Bar, MD
- Scott Huntington, MD, MPH, MSc
- Stephanie Kacik
- Stuart Seropian, MD
- Tarsheen Sethi, MD, MSc
- Last Updated02/09/2025
- Study HIC#2000027145